#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Brief Overview of the Established Practice in Determining the Amino Acid Composition of the CHO Cell Medium
1-1	0-2	2.	_	_	_	_
1-2	3-8	Brief	abstract[1]	new[1]	_	_
1-3	9-17	Overview	abstract[1]	new[1]	_	_
1-4	18-20	of	abstract[1]	new[1]	_	_
1-5	21-24	the	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-6	25-36	Established	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-7	37-45	Practice	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-8	46-48	in	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-9	49-60	Determining	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-10	61-64	the	abstract[1]|abstract[2]|abstract[5]	new[1]|new[2]|new[5]	coref	2-4[11_5]
1-11	65-70	Amino	abstract[1]|abstract[2]|object|person[4]|abstract[5]	new[1]|new[2]|new|new[4]|new[5]	coref	2-17
1-12	71-75	Acid	abstract[1]|abstract[2]|person[4]|abstract[5]	new[1]|new[2]|new[4]|new[5]	_	_
1-13	76-87	Composition	abstract[1]|abstract[2]|abstract[5]	new[1]|new[2]|new[5]	_	_
1-14	88-90	of	abstract[1]|abstract[2]|abstract[5]	new[1]|new[2]|new[5]	_	_
1-15	91-94	the	abstract[1]|abstract[2]|abstract[5]|object[7]	new[1]|new[2]|new[5]|new[7]	_	_
1-16	95-98	CHO	abstract[1]|abstract[2]|abstract[5]|object[6]|object[7]	new[1]|new[2]|new[5]|new[6]|new[7]	_	_
1-17	99-103	Cell	abstract[1]|abstract[2]|abstract[5]|object[6]|object[7]	new[1]|new[2]|new[5]|new[6]|new[7]	_	_
1-18	104-110	Medium	abstract[1]|abstract[2]|abstract[5]|object[7]	new[1]|new[2]|new[5]|new[7]	_	_

#Text=Reports on improving the culture medium composition for CHO cells , specifically in relation to the amino acids , are relatively limited in number .
2-1	111-118	Reports	abstract[8]	new[8]	coref	3-4[0_8]
2-2	119-121	on	abstract[8]	new[8]	_	_
2-3	122-131	improving	abstract[8]	new[8]	_	_
2-4	132-135	the	abstract[8]|abstract[11]	new[8]|giv[11]	coref	18-40[169_11]
2-5	136-143	culture	abstract[8]|abstract|substance[10]|abstract[11]	new[8]|new|new[10]|giv[11]	coref|coref	8-19[0_10]|15-19[136_0]
2-6	144-150	medium	abstract[8]|substance[10]|abstract[11]	new[8]|new[10]|giv[11]	_	_
2-7	151-162	composition	abstract[8]|abstract[11]	new[8]|giv[11]	_	_
2-8	163-166	for	abstract[8]|abstract[11]	new[8]|giv[11]	_	_
2-9	167-170	CHO	abstract[8]|abstract[11]|substance|object[13]	new[8]|giv[11]|new|new[13]	coref|coref	3-18|3-18[22_13]
2-10	171-176	cells	abstract[8]|abstract[11]|object[13]	new[8]|giv[11]|new[13]	_	_
2-11	177-178	,	abstract[8]	new[8]	_	_
2-12	179-191	specifically	abstract[8]	new[8]	_	_
2-13	192-194	in	abstract[8]	new[8]	_	_
2-14	195-203	relation	abstract[8]	new[8]	_	_
2-15	204-206	to	abstract[8]	new[8]	_	_
2-16	207-210	the	abstract[8]|substance[15]	new[8]|new[15]	coref	7-30[42_15]
2-17	211-216	amino	abstract[8]|object|substance[15]	new[8]|giv|new[15]	coref	7-30
2-18	217-222	acids	abstract[8]|substance[15]	new[8]|new[15]	_	_
2-19	223-224	,	_	_	_	_
2-20	225-228	are	_	_	_	_
2-21	229-239	relatively	_	_	_	_
2-22	240-247	limited	_	_	_	_
2-23	248-250	in	_	_	_	_
2-24	251-257	number	abstract	new	coref	7-22[39_0]
2-25	258-259	.	_	_	_	_

#Text=This paucity of reports is strikingly unusual especially considering the widespread use and vast economic importance of CHO cells .
3-1	260-264	This	abstract[17]	new[17]	_	_
3-2	265-272	paucity	abstract[17]	new[17]	_	_
3-3	273-275	of	abstract[17]	new[17]	_	_
3-4	276-283	reports	abstract[17]|abstract	new[17]|giv	_	_
3-5	284-286	is	_	_	_	_
3-6	287-297	strikingly	_	_	_	_
3-7	298-305	unusual	_	_	_	_
3-8	306-316	especially	_	_	_	_
3-9	317-328	considering	_	_	_	_
3-10	329-332	the	event[19]	new[19]	_	_
3-11	333-343	widespread	event[19]	new[19]	_	_
3-12	344-347	use	event[19]	new[19]	_	_
3-13	348-351	and	_	_	_	_
3-14	352-356	vast	abstract[20]	new[20]	_	_
3-15	357-365	economic	abstract[20]	new[20]	_	_
3-16	366-376	importance	abstract[20]	new[20]	_	_
3-17	377-379	of	abstract[20]	new[20]	_	_
3-18	380-383	CHO	abstract[20]|substance|object[22]	new[20]|giv|giv[22]	coref|coref	7-6|7-6[33_22]
3-19	384-389	cells	abstract[20]|object[22]	new[20]|giv[22]	_	_
3-20	390-391	.	_	_	_	_

#Text=2.1.
4-1	392-396	2.1.	abstract	new	_	_

#Text=Statistical Methods : Utilizing Data-Driven Models in Experimental Design
5-1	397-408	Statistical	abstract[24]	new[24]	coref	21-9[184_24]
5-2	409-416	Methods	abstract[24]	new[24]	_	_
5-3	417-418	:	_	_	_	_
5-4	419-428	Utilizing	_	_	_	_
5-5	429-440	Data-Driven	abstract[25]	new[25]	coref	21-18[187_25]
5-6	441-447	Models	abstract[25]	new[25]	_	_
5-7	448-450	in	_	_	_	_
5-8	451-463	Experimental	abstract[26]	new[26]	coref	6-1[27_26]
5-9	464-470	Design	abstract[26]	new[26]	_	_

#Text=Statistical design , also known as design-of-experiments , is arguably the most commonly employed strategy for medium development .
6-1	471-482	Statistical	abstract[27]	giv[27]	coref	6-10[29_27]
6-2	483-489	design	abstract[27]	giv[27]	_	_
6-3	490-491	,	abstract[27]	giv[27]	_	_
6-4	492-496	also	abstract[27]	giv[27]	_	_
6-5	497-502	known	abstract[27]	giv[27]	_	_
6-6	503-505	as	abstract[27]	giv[27]	_	_
6-7	506-527	design-of-experiments	abstract[27]|abstract	giv[27]|new	_	_
6-8	528-529	,	_	_	_	_
6-9	530-532	is	_	_	_	_
6-10	533-541	arguably	abstract[29]	giv[29]	coref	11-7[0_29]
6-11	542-545	the	abstract[29]	giv[29]	_	_
6-12	546-550	most	abstract[29]	giv[29]	_	_
6-13	551-559	commonly	abstract[29]	giv[29]	_	_
6-14	560-568	employed	abstract[29]	giv[29]	_	_
6-15	569-577	strategy	abstract[29]	giv[29]	_	_
6-16	578-581	for	abstract[29]	giv[29]	_	_
6-17	582-588	medium	abstract[29]|event[30]	giv[29]|new[30]	ana	7-13[35_30]
6-18	589-600	development	abstract[29]|event[30]	giv[29]|new[30]	_	_
6-19	601-602	.	_	_	_	_

#Text=Unfortunately most such studies for CHO cells focus on components such as those relevant for the carbon and energy metabolism with only a limited number of studies specifically addressing amino acids .
7-1	603-616	Unfortunately	_	_	_	_
7-2	617-621	most	abstract[31]	new[31]	coref	7-27[40_31]
7-3	622-626	such	abstract[31]	new[31]	_	_
7-4	627-634	studies	abstract[31]	new[31]	_	_
7-5	635-638	for	abstract[31]	new[31]	_	_
7-6	639-642	CHO	abstract[31]|substance|object[33]	new[31]|giv|giv[33]	coref|coref	8-32|9-18[65_33]
7-7	643-648	cells	abstract[31]|object[33]	new[31]|giv[33]	_	_
7-8	649-654	focus	_	_	_	_
7-9	655-657	on	_	_	_	_
7-10	658-668	components	abstract[34]	new[34]	_	_
7-11	669-673	such	abstract[34]	new[34]	_	_
7-12	674-676	as	abstract[34]	new[34]	_	_
7-13	677-682	those	abstract[34]|event[35]	new[34]|giv[35]	coref	8-19[49_35]
7-14	683-691	relevant	abstract[34]|event[35]	new[34]|giv[35]	_	_
7-15	692-695	for	_	_	_	_
7-16	696-699	the	abstract[38]	new[38]	coref	12-16[103_38]
7-17	700-706	carbon	substance|abstract[38]	new|new[38]	_	_
7-18	707-710	and	abstract[38]	new[38]	_	_
7-19	711-717	energy	abstract|abstract[38]	new|new[38]	_	_
7-20	718-728	metabolism	abstract[38]	new[38]	_	_
7-21	729-733	with	_	_	_	_
7-22	734-738	only	abstract[39]	giv[39]	_	_
7-23	739-740	a	abstract[39]	giv[39]	_	_
7-24	741-748	limited	abstract[39]	giv[39]	_	_
7-25	749-755	number	abstract[39]	giv[39]	_	_
7-26	756-758	of	abstract[39]	giv[39]	_	_
7-27	759-766	studies	abstract[39]|abstract[40]	giv[39]|giv[40]	coref	19-6[171_40]
7-28	767-779	specifically	abstract[39]|abstract[40]	giv[39]|giv[40]	_	_
7-29	780-790	addressing	abstract[39]|abstract[40]	giv[39]|giv[40]	_	_
7-30	791-796	amino	abstract[39]|abstract[40]|object|substance[42]	giv[39]|giv[40]|giv|giv[42]	coref|coref	9-6|11-14[88_42]
7-31	797-802	acids	abstract[39]|abstract[40]|substance[42]	giv[39]|giv[40]|giv[42]	_	_
7-32	803-804	.	_	_	_	_

#Text=In line with this observation for statistical methodologies , search heuristics such as genetic algorithms commonly employed in medium development and optimization in various organisms have not been utilized for improving CHO cell medium compositions , even the chemically defined cell-free formulations .
8-1	805-807	In	_	_	_	_
8-2	808-812	line	_	_	_	_
8-3	813-817	with	_	_	_	_
8-4	818-822	this	abstract[43]	new[43]	_	_
8-5	823-834	observation	abstract[43]	new[43]	_	_
8-6	835-838	for	abstract[43]	new[43]	_	_
8-7	839-850	statistical	abstract[43]|abstract[44]	new[43]|new[44]	_	_
8-8	851-864	methodologies	abstract[43]|abstract[44]	new[43]|new[44]	_	_
8-9	865-866	,	_	_	_	_
8-10	867-873	search	event|abstract[46]	new|new[46]	_	_
8-11	874-884	heuristics	abstract[46]	new[46]	_	_
8-12	885-889	such	abstract[46]	new[46]	_	_
8-13	890-892	as	abstract[46]	new[46]	_	_
8-14	893-900	genetic	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-15	901-911	algorithms	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-16	912-920	commonly	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-17	921-929	employed	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-18	930-932	in	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-19	933-939	medium	abstract[46]|abstract[47]|substance|event[49]	new[46]|new[47]|giv|giv[49]	coref|coref	8-34|21-41[0_49]
8-20	940-951	development	abstract[46]|abstract[47]|event[49]	new[46]|new[47]|giv[49]	_	_
8-21	952-955	and	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-22	956-968	optimization	abstract[46]|abstract[47]|abstract	new[46]|new[47]|new	coref	17-13[147_0]
8-23	969-971	in	abstract[46]|abstract[47]	new[46]|new[47]	_	_
8-24	972-979	various	abstract[46]|abstract[47]|animal[51]	new[46]|new[47]|new[51]	_	_
8-25	980-989	organisms	abstract[46]|abstract[47]|animal[51]	new[46]|new[47]|new[51]	_	_
8-26	990-994	have	_	_	_	_
8-27	995-998	not	_	_	_	_
8-28	999-1003	been	_	_	_	_
8-29	1004-1012	utilized	_	_	_	_
8-30	1013-1016	for	_	_	_	_
8-31	1017-1026	improving	_	_	_	_
8-32	1027-1030	CHO	substance|abstract[55]	giv|new[55]	appos|coref	8-37[56_55]|9-18
8-33	1031-1035	cell	place|abstract[55]	new|new[55]	coref	10-31
8-34	1036-1042	medium	substance|abstract[55]	giv|new[55]	coref	18-26
8-35	1043-1055	compositions	abstract[55]	new[55]	_	_
8-36	1056-1057	,	_	_	_	_
8-37	1058-1062	even	abstract[56]	giv[56]	_	_
8-38	1063-1066	the	abstract[56]	giv[56]	_	_
8-39	1067-1077	chemically	abstract[56]	giv[56]	_	_
8-40	1078-1085	defined	abstract[56]	giv[56]	_	_
8-41	1086-1095	cell-free	abstract[56]	giv[56]	_	_
8-42	1096-1108	formulations	abstract[56]	giv[56]	_	_
8-43	1109-1110	.	_	_	_	_

#Text=Low glutamine and high essential amino acid concentrations led to high mAb production against Botulinum A by CHO cells .
9-1	1111-1114	Low	substance[57]	new[57]	coref	10-6[0_57]
9-2	1115-1124	glutamine	substance[57]	new[57]	_	_
9-3	1125-1128	and	_	_	_	_
9-4	1129-1133	high	abstract[60]	new[60]	coref	18-25[161_60]
9-5	1134-1143	essential	substance[59]|abstract[60]	new[59]|new[60]	coref	10-1[67_59]
9-6	1144-1149	amino	object|substance[59]|abstract[60]	giv|new[59]|new[60]	coref	10-2
9-7	1150-1154	acid	substance[59]|abstract[60]	new[59]|new[60]	_	_
9-8	1155-1169	concentrations	abstract[60]	new[60]	_	_
9-9	1170-1173	led	_	_	_	_
9-10	1174-1176	to	_	_	_	_
9-11	1177-1181	high	abstract[62]	new[62]	coref	10-42[80_62]
9-12	1182-1185	mAb	substance|abstract[62]	new|new[62]	coref	10-38
9-13	1186-1196	production	abstract[62]	new[62]	_	_
9-14	1197-1204	against	abstract[62]	new[62]	_	_
9-15	1205-1214	Botulinum	abstract[62]|plant[63]	new[62]|new[63]	_	_
9-16	1215-1216	A	abstract[62]|plant[63]	new[62]|new[63]	_	_
9-17	1217-1219	by	_	_	_	_
9-18	1220-1223	CHO	substance|object[65]	giv|giv[65]	coref|coref	11-27[95_65]|12-17
9-19	1224-1229	cells	object[65]	giv[65]	_	_
9-20	1230-1231	.	_	_	_	_

#Text=An amino acid other than glutamine ( analytically uncharacterized ) was identified as the limiting component in a study that employed response surface methodology to evaluate medium-associated effects on viable cell density ( as a proxy for mAb concentration ) during coupled production and growth .
10-1	1232-1234	An	substance[67]	giv[67]	coref	15-12[133_67]
10-2	1235-1240	amino	object|substance[67]	giv|giv[67]	coref	11-14[87_0]
10-3	1241-1245	acid	substance[67]	giv[67]	_	_
10-4	1246-1251	other	substance[67]	giv[67]	_	_
10-5	1252-1256	than	substance[67]	giv[67]	_	_
10-6	1257-1266	glutamine	substance[67]|substance	giv[67]|giv	_	_
10-7	1267-1268	(	substance[67]	giv[67]	_	_
10-8	1269-1281	analytically	substance[67]	giv[67]	_	_
10-9	1282-1297	uncharacterized	substance[67]	giv[67]	_	_
10-10	1298-1299	)	substance[67]	giv[67]	_	_
10-11	1300-1303	was	_	_	_	_
10-12	1304-1314	identified	_	_	_	_
10-13	1315-1317	as	_	_	_	_
10-14	1318-1321	the	abstract[69]	new[69]	_	_
10-15	1322-1330	limiting	abstract[69]	new[69]	_	_
10-16	1331-1340	component	abstract[69]	new[69]	_	_
10-17	1341-1343	in	_	_	_	_
10-18	1344-1345	a	abstract[70]	new[70]	coref	20-10[180_70]
10-19	1346-1351	study	abstract[70]	new[70]	_	_
10-20	1352-1356	that	abstract[70]	new[70]	_	_
10-21	1357-1365	employed	abstract[70]	new[70]	_	_
10-22	1366-1374	response	abstract[70]|abstract|abstract[72]|abstract[73]	new[70]|new|new[72]|new[73]	coref|coref|coref	18-35|18-35[166_72]|18-35[167_73]
10-23	1375-1382	surface	abstract[70]|abstract[72]|abstract[73]	new[70]|new[72]|new[73]	_	_
10-24	1383-1394	methodology	abstract[70]|abstract[73]	new[70]|new[73]	_	_
10-25	1395-1397	to	_	_	_	_
10-26	1398-1406	evaluate	_	_	_	_
10-27	1407-1424	medium-associated	abstract[74]	new[74]	coref	18-13[156_74]
10-28	1425-1432	effects	abstract[74]	new[74]	_	_
10-29	1433-1435	on	abstract[74]	new[74]	_	_
10-30	1436-1442	viable	abstract[74]|abstract[76]	new[74]|new[76]	coref	13-40[115_76]
10-31	1443-1447	cell	abstract[74]|place|abstract[76]	new[74]|giv|new[76]	coref	12-17[102_0]
10-32	1448-1455	density	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-33	1456-1457	(	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-34	1458-1460	as	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-35	1461-1462	a	abstract[74]|abstract[76]|abstract[77]	new[74]|new[76]|new[77]	_	_
10-36	1463-1468	proxy	abstract[74]|abstract[76]|abstract[77]	new[74]|new[76]|new[77]	_	_
10-37	1469-1472	for	abstract[74]|abstract[76]|abstract[77]	new[74]|new[76]|new[77]	_	_
10-38	1473-1476	mAb	abstract[74]|abstract[76]|abstract[77]|substance|abstract[79]	new[74]|new[76]|new[77]|giv|new[79]	coref|coref	13-20[109_79]|23-17
10-39	1477-1490	concentration	abstract[74]|abstract[76]|abstract[77]|abstract[79]	new[74]|new[76]|new[77]|new[79]	_	_
10-40	1491-1492	)	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-41	1493-1499	during	_	_	_	_
10-42	1500-1507	coupled	abstract[80]	giv[80]	coref	11-23[92_80]
10-43	1508-1518	production	abstract[80]	giv[80]	_	_
10-44	1519-1522	and	_	_	_	_
10-45	1523-1529	growth	abstract	new	coref	11-21
10-46	1530-1531	.	_	_	_	_

#Text=González et al. used the Plackett-Burman design method to optimize the contribution of ten amino acids to the rate of growth and monoclonal antibody production by Chinese hamster ovary cells .
11-1	1532-1540	González	person	new	_	_
11-2	1541-1543	et	_	_	_	_
11-3	1544-1547	al.	_	_	_	_
11-4	1548-1552	used	_	_	_	_
11-5	1553-1556	the	abstract[85]	new[85]	coref	23-1[195_85]
11-6	1557-1572	Plackett-Burman	place|abstract[85]	new|new[85]	coref	18-9
11-7	1573-1579	design	abstract|abstract[85]	giv|new[85]	coref	16-4[139_0]
11-8	1580-1586	method	abstract[85]	new[85]	_	_
11-9	1587-1589	to	_	_	_	_
11-10	1590-1598	optimize	_	_	_	_
11-11	1599-1602	the	abstract[86]	new[86]	_	_
11-12	1603-1615	contribution	abstract[86]	new[86]	_	_
11-13	1616-1618	of	abstract[86]	new[86]	_	_
11-14	1619-1622	ten	abstract[86]|object[87]|substance[88]	new[86]|giv[87]|giv[88]	coref|coref	12-3[0_87]|12-1[97_88]
11-15	1623-1628	amino	abstract[86]|object[87]|substance[88]	new[86]|giv[87]|giv[88]	_	_
11-16	1629-1634	acids	abstract[86]|substance[88]	new[86]|giv[88]	_	_
11-17	1635-1637	to	abstract[86]	new[86]	_	_
11-18	1638-1641	the	abstract[86]|abstract[89]	new[86]|new[89]	coref	13-15[108_89]
11-19	1642-1646	rate	abstract[86]|abstract[89]	new[86]|new[89]	_	_
11-20	1647-1649	of	abstract[86]|abstract[89]	new[86]|new[89]	_	_
11-21	1650-1656	growth	abstract[86]|abstract[89]|abstract	new[86]|new[89]|giv	coref	13-11
11-22	1657-1660	and	abstract[86]|abstract[89]	new[86]|new[89]	_	_
11-23	1661-1671	monoclonal	abstract[86]|abstract[89]|abstract[92]	new[86]|new[89]|giv[92]	coref	23-17[201_92]
11-24	1672-1680	antibody	abstract[86]|abstract[89]|substance|abstract[92]	new[86]|new[89]|new|giv[92]	coref	13-50[117_0]
11-25	1681-1691	production	abstract[86]|abstract[89]|abstract[92]	new[86]|new[89]|giv[92]	_	_
11-26	1692-1694	by	abstract[86]|abstract[89]	new[86]|new[89]	_	_
11-27	1695-1702	Chinese	abstract[86]|abstract[89]|animal[93]|object[95]	new[86]|new[89]|new[93]|giv[95]	coref	16-9[140_95]
11-28	1703-1710	hamster	abstract[86]|abstract[89]|animal[93]|object[95]	new[86]|new[89]|new[93]|giv[95]	_	_
11-29	1711-1716	ovary	abstract[86]|abstract[89]|animal|object[95]	new[86]|new[89]|new|giv[95]	_	_
11-30	1717-1722	cells	abstract[86]|abstract[89]|object[95]	new[86]|new[89]|giv[95]	_	_
11-31	1723-1724	.	_	_	_	_

#Text=These 10 amino acids were specifically identified as per their superior uptake and utilization by the CHO cell metabolism .
12-1	1725-1730	These	substance[97]	giv[97]	ana	12-10[0_97]
12-2	1731-1733	10	substance[97]	giv[97]	_	_
12-3	1734-1739	amino	object|substance[97]	giv|giv[97]	coref	14-10
12-4	1740-1745	acids	substance[97]	giv[97]	_	_
12-5	1746-1750	were	_	_	_	_
12-6	1751-1763	specifically	_	_	_	_
12-7	1764-1774	identified	_	_	_	_
12-8	1775-1777	as	_	_	_	_
12-9	1778-1781	per	_	_	_	_
12-10	1782-1787	their	substance|abstract[99]	giv|new[99]	coref	14-8[125_0]
12-11	1788-1796	superior	abstract[99]	new[99]	_	_
12-12	1797-1803	uptake	abstract[99]	new[99]	_	_
12-13	1804-1807	and	_	_	_	_
12-14	1808-1819	utilization	abstract[100]	new[100]	coref	21-26[189_100]
12-15	1820-1822	by	abstract[100]	new[100]	_	_
12-16	1823-1826	the	abstract[100]|abstract[103]	new[100]|giv[103]	_	_
12-17	1827-1830	CHO	abstract[100]|substance|place[102]|abstract[103]	new[100]|giv|giv[102]|giv[103]	coref	13-25[0_102]
12-18	1831-1835	cell	abstract[100]|place[102]|abstract[103]	new[100]|giv[102]|giv[103]	_	_
12-19	1836-1846	metabolism	abstract[100]|abstract[103]	new[100]|giv[103]	_	_
12-20	1847-1848	.	_	_	_	_

#Text=The analysis was carried out both during exponential phase of growth through monitoring how the specific growth rate and the concentration of the viable cell concentration evolved over time , and during the phase where the cell population reached a very high density , through monitoring of the final monoclonal antibody product concentration and the specific productivity of the cell population .
13-1	1849-1852	The	abstract[104]	new[104]	_	_
13-2	1853-1861	analysis	abstract[104]	new[104]	_	_
13-3	1862-1865	was	_	_	_	_
13-4	1866-1873	carried	_	_	_	_
13-5	1874-1877	out	_	_	_	_
13-6	1878-1882	both	time[105]	new[105]	coref	13-33[112_105]
13-7	1883-1889	during	time[105]	new[105]	_	_
13-8	1890-1901	exponential	time[105]	new[105]	_	_
13-9	1902-1907	phase	time[105]	new[105]	_	_
13-10	1908-1910	of	time[105]	new[105]	_	_
13-11	1911-1917	growth	time[105]|abstract	new[105]|giv	coref	13-17
13-12	1918-1925	through	_	_	_	_
13-13	1926-1936	monitoring	_	_	_	_
13-14	1937-1940	how	_	_	_	_
13-15	1941-1944	the	abstract[108]	giv[108]	_	_
13-16	1945-1953	specific	abstract[108]	giv[108]	_	_
13-17	1954-1960	growth	abstract|abstract[108]	giv|giv[108]	_	_
13-18	1961-1965	rate	abstract[108]	giv[108]	_	_
13-19	1966-1969	and	_	_	_	_
13-20	1970-1973	the	abstract[109]	giv[109]	coref	13-23[111_109]
13-21	1974-1987	concentration	abstract[109]	giv[109]	_	_
13-22	1988-1990	of	abstract[109]	giv[109]	_	_
13-23	1991-1994	the	abstract[109]|abstract[111]	giv[109]|giv[111]	coref	13-48[119_111]
13-24	1995-2001	viable	abstract[109]|abstract[111]	giv[109]|giv[111]	_	_
13-25	2002-2006	cell	abstract[109]|place|abstract[111]	giv[109]|giv|giv[111]	coref	13-37
13-26	2007-2020	concentration	abstract[109]|abstract[111]	giv[109]|giv[111]	_	_
13-27	2021-2028	evolved	_	_	_	_
13-28	2029-2033	over	_	_	_	_
13-29	2034-2038	time	_	_	_	_
13-30	2039-2040	,	_	_	_	_
13-31	2041-2044	and	_	_	_	_
13-32	2045-2051	during	_	_	_	_
13-33	2052-2055	the	time[112]	giv[112]	_	_
13-34	2056-2061	phase	time[112]	giv[112]	_	_
13-35	2062-2067	where	time[112]	giv[112]	_	_
13-36	2068-2071	the	time[112]|abstract[114]	giv[112]|new[114]	coref	13-59[122_114]
13-37	2072-2076	cell	time[112]|place|abstract[114]	giv[112]|giv|new[114]	coref	13-60
13-38	2077-2087	population	time[112]|abstract[114]	giv[112]|new[114]	_	_
13-39	2088-2095	reached	time[112]	giv[112]	_	_
13-40	2096-2097	a	time[112]|abstract[115]	giv[112]|giv[115]	_	_
13-41	2098-2102	very	time[112]|abstract[115]	giv[112]|giv[115]	_	_
13-42	2103-2107	high	time[112]|abstract[115]	giv[112]|giv[115]	_	_
13-43	2108-2115	density	time[112]|abstract[115]	giv[112]|giv[115]	_	_
13-44	2116-2117	,	_	_	_	_
13-45	2118-2125	through	_	_	_	_
13-46	2126-2136	monitoring	event	new	_	_
13-47	2137-2139	of	_	_	_	_
13-48	2140-2143	the	abstract[119]	giv[119]	_	_
13-49	2144-2149	final	abstract[119]	giv[119]	_	_
13-50	2150-2160	monoclonal	substance[117]|abstract[119]	giv[117]|giv[119]	_	_
13-51	2161-2169	antibody	substance[117]|abstract[119]	giv[117]|giv[119]	_	_
13-52	2170-2177	product	abstract|abstract[119]	new|giv[119]	coref	14-22
13-53	2178-2191	concentration	abstract[119]	giv[119]	_	_
13-54	2192-2195	and	_	_	_	_
13-55	2196-2199	the	abstract[120]	new[120]	_	_
13-56	2200-2208	specific	abstract[120]	new[120]	_	_
13-57	2209-2221	productivity	abstract[120]	new[120]	_	_
13-58	2222-2224	of	abstract[120]	new[120]	_	_
13-59	2225-2228	the	abstract[120]|abstract[122]	new[120]|giv[122]	coref	14-19[128_122]
13-60	2229-2233	cell	abstract[120]|place|abstract[122]	new[120]|giv|giv[122]	coref	17-8
13-61	2234-2244	population	abstract[120]|abstract[122]	new[120]|giv[122]	_	_
13-62	2245-2246	.	_	_	_	_

#Text=This investigation aimed to determine which among the ten amino acids were critical for supporting health growth of the population and product formation .
14-1	2247-2251	This	abstract[123]	new[123]	_	_
14-2	2252-2265	investigation	abstract[123]	new[123]	_	_
14-3	2266-2271	aimed	_	_	_	_
14-4	2272-2274	to	_	_	_	_
14-5	2275-2284	determine	_	_	_	_
14-6	2285-2290	which	_	_	_	_
14-7	2291-2296	among	_	_	_	_
14-8	2297-2300	the	substance[125]	giv[125]	coref	16-12[142_125]
14-9	2301-2304	ten	substance[125]	giv[125]	_	_
14-10	2305-2310	amino	object|substance[125]	giv|giv[125]	coref	15-12
14-11	2311-2316	acids	substance[125]	giv[125]	_	_
14-12	2317-2321	were	_	_	_	_
14-13	2322-2330	critical	_	_	_	_
14-14	2331-2334	for	_	_	_	_
14-15	2335-2345	supporting	_	_	_	_
14-16	2346-2352	health	abstract|event[127]	new|new[127]	coref	17-13[0_127]
14-17	2353-2359	growth	event[127]	new[127]	_	_
14-18	2360-2362	of	event[127]	new[127]	_	_
14-19	2363-2366	the	event[127]|abstract[128]	new[127]|giv[128]	coref	17-25[152_128]
14-20	2367-2377	population	event[127]|abstract[128]	new[127]|giv[128]	_	_
14-21	2378-2381	and	_	_	_	_
14-22	2382-2389	product	abstract|event[130]	giv|new[130]	coref|coref	17-22|17-22[150_130]
14-23	2390-2399	formation	event[130]	new[130]	_	_
14-24	2400-2401	.	_	_	_	_

#Text=In return , this information could be utilized for designing an amino acid supplementation regime , through which a superior culture could be achieved through medium improvements .
15-1	2402-2404	In	_	_	_	_
15-2	2405-2411	return	_	_	_	_
15-3	2412-2413	,	_	_	_	_
15-4	2414-2418	this	abstract[131]	new[131]	_	_
15-5	2419-2430	information	abstract[131]	new[131]	_	_
15-6	2431-2436	could	_	_	_	_
15-7	2437-2439	be	_	_	_	_
15-8	2440-2448	utilized	_	_	_	_
15-9	2449-2452	for	_	_	_	_
15-10	2453-2462	designing	_	_	_	_
15-11	2463-2465	an	abstract[135]	new[135]	_	_
15-12	2466-2471	amino	object|substance[133]|abstract[135]	giv|giv[133]|new[135]	coref|coref	16-14|23-13[198_133]
15-13	2472-2476	acid	substance[133]|abstract[135]	giv[133]|new[135]	_	_
15-14	2477-2492	supplementation	substance|abstract[135]	new|new[135]	_	_
15-15	2493-2499	regime	abstract[135]	new[135]	_	_
15-16	2500-2501	,	abstract[135]	new[135]	_	_
15-17	2502-2509	through	abstract[135]	new[135]	_	_
15-18	2510-2515	which	abstract[135]	new[135]	_	_
15-19	2516-2517	a	abstract[135]|abstract[136]	new[135]|giv[136]	coref	17-6[145_136]
15-20	2518-2526	superior	abstract[135]|abstract[136]	new[135]|giv[136]	_	_
15-21	2527-2534	culture	abstract[135]|abstract[136]	new[135]|giv[136]	_	_
15-22	2535-2540	could	abstract[135]	new[135]	_	_
15-23	2541-2543	be	abstract[135]	new[135]	_	_
15-24	2544-2552	achieved	abstract[135]	new[135]	_	_
15-25	2553-2560	through	abstract[135]	new[135]	_	_
15-26	2561-2567	medium	abstract[135]|event[137]	new[135]|new[137]	_	_
15-27	2568-2580	improvements	abstract[135]|event[137]	new[135]|new[137]	_	_
15-28	2581-2582	.	_	_	_	_

#Text=The authors proposed a two-stage strategy for providing the cells with the key amino acids .
16-1	2583-2586	The	person[138]	new[138]	_	_
16-2	2587-2594	authors	person[138]	new[138]	_	_
16-3	2595-2603	proposed	_	_	_	_
16-4	2604-2605	a	abstract[139]	giv[139]	coref	18-8[155_139]
16-5	2606-2615	two-stage	abstract[139]	giv[139]	_	_
16-6	2616-2624	strategy	abstract[139]	giv[139]	_	_
16-7	2625-2628	for	abstract[139]	giv[139]	_	_
16-8	2629-2638	providing	abstract[139]	giv[139]	_	_
16-9	2639-2642	the	abstract[139]|object[140]	giv[139]|giv[140]	_	_
16-10	2643-2648	cells	abstract[139]|object[140]	giv[139]|giv[140]	_	_
16-11	2649-2653	with	abstract[139]	giv[139]	_	_
16-12	2654-2657	the	abstract[139]|substance[142]	giv[139]|giv[142]	coref	18-16[158_142]
16-13	2658-2661	key	abstract[139]|substance[142]	giv[139]|giv[142]	_	_
16-14	2662-2667	amino	abstract[139]|object|substance[142]	giv[139]|giv|giv[142]	coref	18-16
16-15	2668-2673	acids	abstract[139]|substance[142]	giv[139]|giv[142]	_	_
16-16	2674-2675	.	_	_	_	_

#Text=One stage focused on achieving a healthy cell culture through focusing on growth optimization , and a second stage which optimizes product formation once a large cell population has been achieved .
17-1	2676-2679	One	abstract[143]	new[143]	coref	17-17[148_143]
17-2	2680-2685	stage	abstract[143]	new[143]	_	_
17-3	2686-2693	focused	_	_	_	_
17-4	2694-2696	on	_	_	_	_
17-5	2697-2706	achieving	_	_	_	_
17-6	2707-2708	a	abstract[145]	giv[145]	_	_
17-7	2709-2716	healthy	abstract[145]	giv[145]	_	_
17-8	2717-2721	cell	place|abstract[145]	giv|giv[145]	coref	17-27
17-9	2722-2729	culture	abstract[145]	giv[145]	_	_
17-10	2730-2737	through	_	_	_	_
17-11	2738-2746	focusing	_	_	_	_
17-12	2747-2749	on	_	_	_	_
17-13	2750-2756	growth	event|abstract[147]	giv|giv[147]	coref	18-20
17-14	2757-2769	optimization	abstract[147]	giv[147]	_	_
17-15	2770-2771	,	_	_	_	_
17-16	2772-2775	and	_	_	_	_
17-17	2776-2777	a	abstract[148]	giv[148]	_	_
17-18	2778-2784	second	abstract[148]	giv[148]	_	_
17-19	2785-2790	stage	abstract[148]	giv[148]	_	_
17-20	2791-2796	which	abstract[148]	giv[148]	_	_
17-21	2797-2806	optimizes	abstract[148]	giv[148]	_	_
17-22	2807-2814	product	abstract[148]|abstract|event[150]	giv[148]|giv|giv[150]	_	_
17-23	2815-2824	formation	abstract[148]|event[150]	giv[148]|giv[150]	_	_
17-24	2825-2829	once	_	_	_	_
17-25	2830-2831	a	abstract[152]	giv[152]	_	_
17-26	2832-2837	large	abstract[152]	giv[152]	_	_
17-27	2838-2842	cell	place|abstract[152]	giv|giv[152]	_	_
17-28	2843-2853	population	abstract[152]	giv[152]	_	_
17-29	2854-2857	has	_	_	_	_
17-30	2858-2862	been	_	_	_	_
17-31	2863-2871	achieved	_	_	_	_
17-32	2872-2873	.	_	_	_	_

#Text=More recently , Torkashvand et al. used the Plackett-Burman design to screen the effects of amino acids on promoting growth , and then optimized the medium concentrations of a combination of amino acids using response surface methodology to determine the feed composition .
18-1	2874-2878	More	_	_	_	_
18-2	2879-2887	recently	_	_	_	_
18-3	2888-2889	,	_	_	_	_
18-4	2890-2901	Torkashvand	person	new	_	_
18-5	2902-2904	et	_	_	_	_
18-6	2905-2908	al.	_	_	_	_
18-7	2909-2913	used	_	_	_	_
18-8	2914-2917	the	abstract[155]	giv[155]	coref	19-28[0_155]
18-9	2918-2933	Plackett-Burman	place|abstract[155]	giv|giv[155]	_	_
18-10	2934-2940	design	abstract[155]	giv[155]	_	_
18-11	2941-2943	to	_	_	_	_
18-12	2944-2950	screen	_	_	_	_
18-13	2951-2954	the	abstract[156]	giv[156]	_	_
18-14	2955-2962	effects	abstract[156]	giv[156]	_	_
18-15	2963-2965	of	abstract[156]	giv[156]	_	_
18-16	2966-2971	amino	abstract[156]|object|substance[158]	giv[156]|giv|giv[158]	coref|coref	18-32|18-32[164_158]
18-17	2972-2977	acids	abstract[156]|substance[158]	giv[156]|giv[158]	_	_
18-18	2978-2980	on	_	_	_	_
18-19	2981-2990	promoting	_	_	_	_
18-20	2991-2997	growth	event	giv	ana	19-9
18-21	2998-2999	,	_	_	_	_
18-22	3000-3003	and	_	_	_	_
18-23	3004-3008	then	_	_	_	_
18-24	3009-3018	optimized	_	_	_	_
18-25	3019-3022	the	abstract[161]	giv[161]	_	_
18-26	3023-3029	medium	substance|abstract[161]	giv|giv[161]	coref	21-40
18-27	3030-3044	concentrations	abstract[161]	giv[161]	_	_
18-28	3045-3047	of	abstract[161]	giv[161]	_	_
18-29	3048-3049	a	abstract[161]|abstract[162]	giv[161]|new[162]	_	_
18-30	3050-3061	combination	abstract[161]|abstract[162]	giv[161]|new[162]	_	_
18-31	3062-3064	of	abstract[161]|abstract[162]	giv[161]|new[162]	_	_
18-32	3065-3070	amino	abstract[161]|abstract[162]|object|substance[164]	giv[161]|new[162]|giv|giv[164]	_	_
18-33	3071-3076	acids	abstract[161]|abstract[162]|substance[164]	giv[161]|new[162]|giv[164]	_	_
18-34	3077-3082	using	_	_	_	_
18-35	3083-3091	response	abstract|abstract[166]|abstract[167]	giv|giv[166]|giv[167]	_	_
18-36	3092-3099	surface	abstract[166]|abstract[167]	giv[166]|giv[167]	_	_
18-37	3100-3111	methodology	abstract[167]	giv[167]	_	_
18-38	3112-3114	to	_	_	_	_
18-39	3115-3124	determine	_	_	_	_
18-40	3125-3128	the	abstract[169]	giv[169]	coref	23-13[199_169]
18-41	3129-3133	feed	substance|abstract[169]	new|giv[169]	_	_
18-42	3134-3145	composition	abstract[169]	giv[169]	_	_
18-43	3146-3147	.	_	_	_	_

#Text=Although statistics were employed in these studies , it would be very difficult to extract learning as to the nature of the potential benefits of employing different design approaches
19-1	3148-3156	Although	_	_	_	_
19-2	3157-3167	statistics	abstract	new	_	_
19-3	3168-3172	were	_	_	_	_
19-4	3173-3181	employed	_	_	_	_
19-5	3182-3184	in	_	_	_	_
19-6	3185-3190	these	abstract[171]	giv[171]	_	_
19-7	3191-3198	studies	abstract[171]	giv[171]	_	_
19-8	3199-3200	,	_	_	_	_
19-9	3201-3203	it	event	giv	_	_
19-10	3204-3209	would	_	_	_	_
19-11	3210-3212	be	_	_	_	_
19-12	3213-3217	very	_	_	_	_
19-13	3218-3227	difficult	_	_	_	_
19-14	3228-3230	to	_	_	_	_
19-15	3231-3238	extract	_	_	_	_
19-16	3239-3247	learning	abstract[173]	new[173]	_	_
19-17	3248-3250	as	abstract[173]	new[173]	_	_
19-18	3251-3253	to	abstract[173]	new[173]	_	_
19-19	3254-3257	the	abstract[173]|abstract[174]	new[173]|new[174]	_	_
19-20	3258-3264	nature	abstract[173]|abstract[174]	new[173]|new[174]	_	_
19-21	3265-3267	of	abstract[173]|abstract[174]	new[173]|new[174]	_	_
19-22	3268-3271	the	abstract[173]|abstract[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
19-23	3272-3281	potential	abstract[173]|abstract[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
19-24	3282-3290	benefits	abstract[173]|abstract[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
19-25	3291-3293	of	abstract[173]|abstract[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
19-26	3294-3303	employing	abstract[173]|abstract[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
19-27	3304-3313	different	abstract[173]|abstract[174]|abstract[175]|abstract[177]	new[173]|new[174]|new[175]|new[177]	_	_
19-28	3314-3320	design	abstract[173]|abstract[174]|abstract[175]|abstract|abstract[177]	new[173]|new[174]|new[175]|giv|new[177]	_	_
19-29	3321-3331	approaches	abstract[173]|abstract[174]|abstract[175]|abstract[177]	new[173]|new[174]|new[175]|new[177]	_	_

#Text=since these investigations focused on the empirical aspects of the study rather than providing an in-depth evaluation of the statistical tools employed .
20-1	3332-3337	since	_	_	_	_
20-2	3338-3343	these	abstract[178]	new[178]	_	_
20-3	3344-3358	investigations	abstract[178]	new[178]	_	_
20-4	3359-3366	focused	_	_	_	_
20-5	3367-3369	on	_	_	_	_
20-6	3370-3373	the	abstract[179]	new[179]	_	_
20-7	3374-3383	empirical	abstract[179]	new[179]	_	_
20-8	3384-3391	aspects	abstract[179]	new[179]	_	_
20-9	3392-3394	of	abstract[179]	new[179]	_	_
20-10	3395-3398	the	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
20-11	3399-3404	study	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
20-12	3405-3411	rather	_	_	_	_
20-13	3412-3416	than	_	_	_	_
20-14	3417-3426	providing	_	_	_	_
20-15	3427-3429	an	abstract[181]	new[181]	_	_
20-16	3430-3438	in-depth	abstract[181]	new[181]	_	_
20-17	3439-3449	evaluation	abstract[181]	new[181]	_	_
20-18	3450-3452	of	abstract[181]	new[181]	_	_
20-19	3453-3456	the	abstract[181]|abstract[182]	new[181]|new[182]	ana	21-3[0_182]
20-20	3457-3468	statistical	abstract[181]|abstract[182]	new[181]|new[182]	_	_
20-21	3469-3474	tools	abstract[181]|abstract[182]	new[181]|new[182]	_	_
20-22	3475-3483	employed	abstract[181]|abstract[182]	new[181]|new[182]	_	_
20-23	3484-3485	.	_	_	_	_

#Text=Consequently , they fail to compare and contrast different methods and provide reasoning for the selection of certain models over others , or point towards the utilization of favorable statistical designs , which could prove invaluable to attain systematic medium development strategies .
21-1	3486-3498	Consequently	_	_	_	_
21-2	3499-3500	,	_	_	_	_
21-3	3501-3505	they	abstract	giv	_	_
21-4	3506-3510	fail	_	_	_	_
21-5	3511-3513	to	_	_	_	_
21-6	3514-3521	compare	_	_	_	_
21-7	3522-3525	and	_	_	_	_
21-8	3526-3534	contrast	_	_	_	_
21-9	3535-3544	different	abstract[184]	giv[184]	coref	24-1[203_184]
21-10	3545-3552	methods	abstract[184]	giv[184]	_	_
21-11	3553-3556	and	_	_	_	_
21-12	3557-3564	provide	_	_	_	_
21-13	3565-3574	reasoning	abstract[185]	new[185]	_	_
21-14	3575-3578	for	abstract[185]	new[185]	_	_
21-15	3579-3582	the	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-16	3583-3592	selection	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-17	3593-3595	of	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-18	3596-3603	certain	abstract[185]|abstract[186]|abstract[187]	new[185]|new[186]|giv[187]	_	_
21-19	3604-3610	models	abstract[185]|abstract[186]|abstract[187]	new[185]|new[186]|giv[187]	_	_
21-20	3611-3615	over	abstract[185]|abstract[186]|abstract[187]	new[185]|new[186]|giv[187]	_	_
21-21	3616-3622	others	abstract[185]|abstract[186]|abstract[187]|person	new[185]|new[186]|giv[187]|new	_	_
21-22	3623-3624	,	_	_	_	_
21-23	3625-3627	or	_	_	_	_
21-24	3628-3633	point	_	_	_	_
21-25	3634-3641	towards	_	_	_	_
21-26	3642-3645	the	abstract[189]	giv[189]	_	_
21-27	3646-3657	utilization	abstract[189]	giv[189]	_	_
21-28	3658-3660	of	abstract[189]	giv[189]	_	_
21-29	3661-3670	favorable	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-30	3671-3682	statistical	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-31	3683-3690	designs	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-32	3691-3692	,	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-33	3693-3698	which	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-34	3699-3704	could	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-35	3705-3710	prove	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-36	3711-3721	invaluable	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-37	3722-3724	to	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-38	3725-3731	attain	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
21-39	3732-3742	systematic	abstract[189]|abstract[190]|abstract[193]	giv[189]|new[190]|new[193]	_	_
21-40	3743-3749	medium	abstract[189]|abstract[190]|substance|abstract[193]	giv[189]|new[190]|giv|new[193]	_	_
21-41	3750-3761	development	abstract[189]|abstract[190]|event|abstract[193]	giv[189]|new[190]|giv|new[193]	_	_
21-42	3762-3772	strategies	abstract[189]|abstract[190]|abstract[193]	giv[189]|new[190]|new[193]	_	_
21-43	3773-3774	.	_	_	_	_

#Text=2.2. Metabolic Profiling
22-1	3775-3779	2.2.	_	_	_	_
22-2	3780-3789	Metabolic	abstract[194]	new[194]	_	_
22-3	3790-3799	Profiling	abstract[194]	new[194]	_	_

#Text=Another method widely used in the industry to understand the impact of amino acid composition on mAb production is exo- and endo-metabolic profiling .
23-1	3800-3807	Another	abstract[195]	giv[195]	coref	23-20[202_195]
23-2	3808-3814	method	abstract[195]	giv[195]	_	_
23-3	3815-3821	widely	abstract[195]	giv[195]	_	_
23-4	3822-3826	used	abstract[195]	giv[195]	_	_
23-5	3827-3829	in	abstract[195]	giv[195]	_	_
23-6	3830-3833	the	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
23-7	3834-3842	industry	abstract[195]|abstract[196]	giv[195]|new[196]	_	_
23-8	3843-3845	to	_	_	_	_
23-9	3846-3856	understand	_	_	_	_
23-10	3857-3860	the	abstract[197]	new[197]	_	_
23-11	3861-3867	impact	abstract[197]	new[197]	_	_
23-12	3868-3870	of	abstract[197]	new[197]	_	_
23-13	3871-3876	amino	abstract[197]|substance[198]|abstract[199]	new[197]|giv[198]|giv[199]	_	_
23-14	3877-3881	acid	abstract[197]|substance[198]|abstract[199]	new[197]|giv[198]|giv[199]	_	_
23-15	3882-3893	composition	abstract[197]|abstract[199]	new[197]|giv[199]	_	_
23-16	3894-3896	on	abstract[197]	new[197]	_	_
23-17	3897-3900	mAb	abstract[197]|substance|abstract[201]	new[197]|giv|giv[201]	_	_
23-18	3901-3911	production	abstract[197]|abstract[201]	new[197]|giv[201]	_	_
23-19	3912-3914	is	_	_	_	_
23-20	3915-3919	exo-	abstract[202]	giv[202]	_	_
23-21	3920-3923	and	abstract[202]	giv[202]	_	_
23-22	3924-3938	endo-metabolic	abstract[202]	giv[202]	_	_
23-23	3939-3948	profiling	abstract[202]	giv[202]	_	_
23-24	3949-3950	.	_	_	_	_

#Text=Such methods are purely empirical and are mainly utilized to improve an established platform process , by suggesting specific nutrients to be added during the course of a cultivation , for example , rather than to conduct a broad de novo exploration .
24-1	3951-3955	Such	abstract[203]	giv[203]	_	_
24-2	3956-3963	methods	abstract[203]	giv[203]	_	_
24-3	3964-3967	are	_	_	_	_
24-4	3968-3974	purely	_	_	_	_
24-5	3975-3984	empirical	_	_	_	_
24-6	3985-3988	and	_	_	_	_
24-7	3989-3992	are	_	_	_	_
24-8	3993-3999	mainly	_	_	_	_
24-9	4000-4008	utilized	_	_	_	_
24-10	4009-4011	to	_	_	_	_
24-11	4012-4019	improve	_	_	_	_
24-12	4020-4022	an	abstract[205]	new[205]	_	_
24-13	4023-4034	established	abstract[205]	new[205]	_	_
24-14	4035-4043	platform	abstract|abstract[205]	new|new[205]	_	_
24-15	4044-4051	process	abstract[205]	new[205]	_	_
24-16	4052-4053	,	_	_	_	_
24-17	4054-4056	by	_	_	_	_
24-18	4057-4067	suggesting	_	_	_	_
24-19	4068-4076	specific	substance[206]	new[206]	_	_
24-20	4077-4086	nutrients	substance[206]	new[206]	_	_
24-21	4087-4089	to	substance[206]	new[206]	_	_
24-22	4090-4092	be	substance[206]	new[206]	_	_
24-23	4093-4098	added	substance[206]	new[206]	_	_
24-24	4099-4105	during	substance[206]	new[206]	_	_
24-25	4106-4109	the	substance[206]|time[207]	new[206]|new[207]	_	_
24-26	4110-4116	course	substance[206]|time[207]	new[206]|new[207]	_	_
24-27	4117-4119	of	substance[206]|time[207]	new[206]|new[207]	_	_
24-28	4120-4121	a	substance[206]|time[207]|event[208]	new[206]|new[207]|new[208]	_	_
24-29	4122-4133	cultivation	substance[206]|time[207]|event[208]	new[206]|new[207]|new[208]	_	_
24-30	4134-4135	,	_	_	_	_
24-31	4136-4139	for	_	_	_	_
24-32	4140-4147	example	_	_	_	_
24-33	4148-4149	,	_	_	_	_
24-34	4150-4156	rather	_	_	_	_
24-35	4157-4161	than	_	_	_	_
24-36	4162-4164	to	_	_	_	_
24-37	4165-4172	conduct	_	_	_	_
24-38	4173-4174	a	event[209]	new[209]	_	_
24-39	4175-4180	broad	event[209]	new[209]	_	_
24-40	4181-4183	de	event[209]	new[209]	_	_
24-41	4184-4188	novo	event[209]	new[209]	_	_
24-42	4189-4200	exploration	event[209]	new[209]	_	_
24-43	4201-4202	.	_	_	_	_
